Jade Biosciences doses first participant in Phase 1 trial of autoimmune drug candidate JADE201

Jade Biosciences

Jade Biosciences

JBIO

0.00
  • Jade Biosciences dosed the first participant in a first-in-human Phase 1 trial of JADE201 in rheumatoid arthritis.
  • Interim Phase 1 results have not been presented; readouts are expected in 2027.
  • The study will evaluate whether JADE201 can show an acceptable safety profile with evidence of the intended B-cell effects.
  • The 2027 data are expected to guide which autoimmune indications move forward, shaping portfolio focus and development spending.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605261605PRIMZONEFULLFEED9726153) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.